Epigenetics has been defined as 'the structural adaptation of chromosomal regions so as to register, signal or perpetuate altered activity states.' Currently, several classes of anticancer drugs function at the epigenetic level, including inhibitors of DNA methyltransferase, histone deacetylase (HDAC), lysine-specific demethylase 1, zeste homolog 2, and bromodomain and extraterminal motif (BET) proteins. BET proteins have multiple functions, including the initiation and elongation of transcription and cell cycle regulation. In recent years, inhibitors of BET proteins have been developed as anticancer agents. These inhibitors exhibit selectivity for tumor cells by preferentially binding to superenhancers, noncoding regions of DNA critical for the transcription of genes that determine a cell's identity. Preclinical research on BET inhibitors has identified them as a potential means of targeting MYC. Early clinical trials with BET inhibitors have had mixed results, with few responses in both hematologic and solid tumors that tend to be short-lived. Toxicities have included severe, thrombocytopenia, fatigue, nausea, vomiting, and diarrhea; GI sideeffects, fatigue, and low-grade dysgeusia have limited compliance. However, preclinical data suggest that BET inhibitors may have a promising future in combination with other agents. They appear to be able to overcome resistance to targeted agents and have strong synergy with immune checkpoint inhibitors as well as with multiple epigenetic agents, particularly HDAC inhibitors. In many instances, BET and HDAC inhibitors were synergistic at reduced doses, suggesting a potential means of avoiding the overlapping toxicities of the two drug classes. BET inhibitors provide a novel approach to epigenetic anticancer therapy. However, to date they appear to have limited efficacy as single agents. A focus on BET inhibitors in combination with other drugs such as targeted and/or as other epigenetic agents is warranted, due to limited monotherapy activity, including pharmacodynamic correlatives differential activity amongst select drug combinations.
Introduction
As clinical oncology becomes increasingly precision oriented, a promising, yet seemingly generalized, approach has emerged in the form of epigenetics. In 2007, Adrian Bird suggested it be defined as 'the structural adaptation of chromosomal regions so as to register, signal or perpetuate altered activity states' [1] . Subsequently, a group of experts who met at Cold Spring Harbor in December 2008 defined an epigenetic trait as 'a stably heritable phenotype resulting from changes in a chromosome without alterations in the DNA sequence' [2] . Clearly, modifications to DNA and its associated histone proteins play a significant role in the regulation of gene expression [3] [4] [5] .
In mammalian cells, condensed nuclear DNA is wrapped around a core of eight histone proteins, comprising units of chromatin which can be modified in several ways. Methylation, acetylation, ubiquitination, phosphorylation, and glycosylation are among the histone modifying processes involved in cancer [6] . These modifications regulate the expression of genes controlling cell cycle proliferation, DNA repair and mitosis, amongst others, and have been unequivocally linked to tumorigenesis and tumor progression [7] . Currently, several drug classes harness epigenetics to treat human cancers, including DNA methyltransferase inhibitors, histone deacetylase (HDAC) inhibitors, lysinespecific demethylase 1 (LSD1) inhibitors, enhancer of zeste homolog 2 (EZH2) inhibitors, and bromodomain and extraterminal motif (BET) inhibitors.
DNA methyltransferase inhibitors such as azacitadine and decitabine, FDA approved for the treatment of myelodysplastic syndrome (MDS), inhibit the addition of methyl groups to the DNA wrapped around histone proteins by enzymes called DNA methytransferases (DNMTs) [8, 9] . These agents cause global hypomethylation and ultimately lead to DNA damage and cell death [10] . Histones themselves have an accessible lysine rich amino-terminal that can be both acetylated and methylated. Writer proteins called histone acetyltransferases add an acetyl group to this tail and induce a looser configuration of chromatin (euchromatin) that promotes transcription. Eraser proteins called HDACs remove these acetyl groups and return chromatin to a less accessible configuration (heterochromatin), repressing transcription [ Figure 1 ] 11 -13] .
HDAC proteins are involved in oncogenesis in multiple ways. For example, they can prevent the expression of tumor suppressor genes when they are recruited to promoters alongside fusion oncogenes such as PML-RARa. HDACs are also globally overexpressed in multiple tumor types with the degree of overexpression correlated with poorer prognosis [14] . The first HDAC inhibitor, vorinostat, was approved in 2006 for the treatment of cutaneous T-cell lymphoma [15, 16] . Since then, romidepsin, panobinostat, and belinostat have been approved by the FDA for the treatment of peripheral T-cell lymphoma and multiple myeloma. These drugs appear to inhibit oncogenesis by promoting apoptosis and cell cycle arrest and altering the DNA damage pathway [17] .
BET proteins: function and inhibition
Another class of epigenetic targets is the BET proteins, a protein family known to be overexpressed in multiple tumor types [18] . The family consists of four BET proteins: Brd2, Brd3, Brd4, and bromodomain testis-specific protein (BRDT), the latter of which is expressed in germ cells. These proteins contain two N-terminal bromodomains which bind to acetylated lysine residues on histone tails. Brd4 in particular has been of interest as it forms a fusion oncoprotein with the nuclear protein in testis (NUT) protein as a result of a t(15;19) translocation, resulting in the rare but universally fatal nut midline carcinoma (NMC) [19] . Thus, the BET fusion oncoprotein itself serves as the disease's driver, as opposed to other malignancies in which BET proteins play a more indirect role. BET proteins have multiple mechanisms of action, the two best understood of which are transcriptional and cell cycle regulation. BET proteins play key roles in both initiating and continuing transcription. Brd2 is one component of the Mediator complex, a collection of associated proteins which bind to RNA Polymerase II (Pol II) to initiate transcription [20] . Brd2 forms a complex with Pol II and E2F transcription factors, escorting the latter to the Cyclin A promoter [21] [22] [23] . Along with E2F proteins, Brd2 also activates the promoters of several cell cycle regulatory genes, including Cyclin D11 and Cyclin E [24] . Brd4 functions as a Ser2 kinase, phosphorylating the C terminal domain Serine 2 on Pol II, which is critical for initiating transcription [25] . Brd4 also plays a role in elongating transcription by recruiting the positive transcription elongation factor (PTEFb) to promoters [Figures 2A and 2B] [26] . Thus, Brd4 is integrally involved in both initiating transcription, via its Ser2 kinase action, and elongating transcription, via its interaction with PTEFb [27] . The extraterminal (nonbromodomain) region of BET proteins also regulates transcription by interacting with other key proteins [28, 29] .
BET proteins also play key roles in cell cycle regulation. Brd4 serves as both a mitotic bookmark and a cell cycle gatekeeper.
Unlike most epigenetic modifiers, Brd4 remains bound to chromosomes during mitosis [30] . In particular, it binds to acetylated H3 and H4 [31] , bookmarking genes which will be transcribed in late mitosis and early G1 [32] . Brd4 is also necessary for cell cycle progression; knockdown of Brd4 results in G1 arrest [33, 34] . In part, this may be due to its role in regulating the expression of Aurora B kinase (AURKB), which is critical for chromosome segregation during mitosis [35] .
Over the last 6 years, several novel inhibitors of BET proteins have been developed with varying degrees of antitumor activity. These inhibitors may provide potentially novel therapeutic approaches to multiple cancer types, particularly in combination with other small molecule inhibitors and epigenetic regulators [36] [37] [38] [39] [40] . The first two BET inhibitors were described in 2010. I-BET, a benzodiazepene derivative, was found to selectively downregulate the expression of proinflammatory genes and transcription factors [41] . The second BET inhibitor described, JQ1, has become the archetypal molecule of its class. JQ1 displaces Brd4 from chromatin and induces differentiation, G1 cell cycle arrest, and apoptosis in human-derived NMC lines. In patient-derived xenograft models, JQ1 halted cell cycle progression in tumor cells and induced apoptosis [42] . Since it was first described, JQ1 has become a tool for a large body of preclinical work on BET inhibition, in part because it was offered as an open source technology to researchers. However, select pharmacologic characteristics, such as its short half-life of one hour, preclude its clinical use and limit the ability to translate preclinical success stories into clinical benefit [43] .
Preclinical work with BET inhibitors has further supported our understanding of how BET proteins regulate the cell cycle. Several BET inhibitors have been observed to cause G1 arrest in models of hematologic and solid malignancies [42, 44, 45] . The BET inhibitor PFI-1 downregulates AURKB expression, confirming earlier findings that Brd4 regulates AURKB and suggesting that the kinase could serve as a potential secondary target in future combination studies [44] . In MLL cell lines, treatment with the BET inhibitor I-BET151 inhibited the transcription of BCL2, MYC, and CDK6, all of which are critical to cell cycle progression [ Figure 3 ] [46] . In melanoma cell lines, the BET inhibitor MS417 caused downregulation of the critical cell cycle genes MYC, ERK1, and SKP2 and upregulation of cyclin dependent kinase inhibitors p21 and p27. Also observed were tumor regression and a reduced metastatic burden in xenograft models [18] .
Based on their mechanisms of action, BET inhibition might be expected to cause generalized transcriptional repression and cell cycle arrest. Yet in preclinical models, BET inhibitors target tumor cells and do not affect normal tissues. This selectivity appears to be mediated by the inhibitors' preferential binding to superenhancers, which are noncoding regions of DNA which bind multiple transcription factors and are critical to the expression of a cell's identity [47, 48] . In the laboratory, researchers have found that Brd4 normally localizes to superenhancers; it appears that JQ1 does the same, limiting Brd4 binding in these critical regions and contributing to the drug's tumor-specific effects [45, 49] .
A novel approach to targeting MYC
The MYC gene family encodes the multipurpose Myc protein which promotes cell growth and differentiation, cell cycle progression, and apoptosis, among many activities. Deregulated Myc is frequently implicated in human oncogenesis, with translocations and rearrangements of C-MYC resulting in high Myc protein levels in many hematologic malignancies, whereas amplification and overexpression are most commonly observed in solid tumors. Despite the potential therapeutic benefit of reversing Myc deregulation, clinically beneficial Myc inhibitors have yet to be identified [50, 51] . The first observation that Myc regulation might be implicated in BET protein function was based on the discovery that PTEFb was not recruited to the C-MYC locus during G1 in Brd4 knockdown cells, suggesting that Brd4 is critical for C-MYC transcription [28] .
In many instances, BET inhibition results in downregulation of MYC expression, which was measured by reduced mRNA and protein levels when mouse MLL-fusion leukemia cells were treated with JQ1 [52] . In multiple myeloma cell lines, JQ1 and I-BET151 inhibited transcription of MYC, in some instances in a dose-dependent manner [53] [54] [55] . These effects appear to be intensified in MYC-amplified tumors; JQ1 was found to induce apoptosis and inhibit cell proliferation more strongly in MYCamplified medulloblastoma cell lines [56] .
However, it is clear that we know only part of the MYC story. In a high throughput pharmacogenomic screen of JQ1 in 673 cell lines, Puissant et al. found a clear relationship between MYC amplification and sensitivity to JQ1; however, only 4 of the 99 sensitive cell lines were MYC-amplified [57] . In preclinical studies with other BET inhibitors, basal levels of MYC mRNA have not correlated well with drug sensitivity [58, 59] . Overall, current results do not clarify whether the extent of MYC downregulation is necessarily correlated with response.
The complex relationship between MYC regulation and sensitivity to BET inhibition may be due to the multiple mechanisms of BET protein function. For example, when ectopic Myc was added to in vitro and in vivo models of MYC-amplified neuroblastoma sensitive to the BET inhibitor OTX015, the antiproliferative activity of the compound was not compromised, suggesting the importance of other mechanisms of BET inhibition [60] . It may be the case that MYC deregulation predicts sensitivity to BET inhibition but that downregulation of its expression does not play an essential role in the growth restriction induced by these compounds. Certainly, the effects of MYC suppression are not uniform across tumor types. While the potential of BET inhibitors as anti-MYC drugs is great, it will be critical to assess MYC downregulation and its relationship to drug response in early clinical trials.
Early clinical results with BET inhibitors
Currently, there are 13 BET inhibitors in early phase clinical trials ( Table 1 ). The first phase I clinical trials using BET inhibitors have been reported very recently with mixed results ( Table 2 ). The first clinical activity was reported in 2014 as preliminary data from a phase 1 dose escalation study of the agent MK-8628/ OTX015 in advanced acute leukemia [61] . Recently, the mature results of the larger, European and North American phase 1 dose escalation study of OTX015 in hematologic malignancies were reported. The nonleukemia cohort comprised 33 patients with relapsed or refractory lymphoma and 12 patients with relapsed or refractory multiple myeloma; on average, patients had received three prior therapies. Three patients with diffuse large B cell lympohma (DLBCL) had partial responses (PRs) to the drug, while two additional patients experienced symptomatic improvement. No responses were observed in the myeloma patients. Interestingly, 11 of the 12 DLBCL patients underwent retrospective c-Myc immunohistochemical (IHC) testing and five were positive. However, only one of these responded to the drug. Dose-limiting toxicities were reversible thrombocytopenia, neutropenia, and hyponatremia [62] . The leukemia cohort was reported separately and consisted of 41 patients, 36 of whom had AML. In addition to two CRs lasting three and five months, one patient had a CRi for two months (incomplete recovery of platelet count) and two experienced partial blast clearance. However, no patients, including responders, were observed to have mRNA downregulation in C-MYC, BCL2, CCND1, or NF-jB. DLTs included diarrhea and fatigue; additional toxicities, including nausea, skin changes, and lower grade diarrhea and fatigue, made compliance difficult [63] .
Preliminary phase 1 results in hematologic malignancies with CPI-0610, another BET inhibitor, have been reported. A dose escalation study of CPI-0610 in 44 patients with relapsed or refractory lymphoma, half of whom had received four or more prior lines of therapy, was notable for two complete responses (CR), one PR, five patients with lesser responses not qualifying as a PR, and six patients with stable disease. Dose-dependent, noncumulative, reversible thrombocytopenia was observed as was grade 3 diarrhea in one patient; the maximum-tolerated dose (MTD) has not yet been established [64] .
Multiple early phase clinical trials of BET inhibitors are ongoing in solid tumors, and early data was presented at the 2016 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. A phase Ib trial of OTX015 in 47 patients with advanced solid tumors demonstrated four PRs [3 in NMC, 1 in castrate-resistant prostate cancer (CRPC)] and 7 patients with sustained stable disease for 4-8 months. Toxicities included grade 3 and 4 thrombocytopenia (20%), grade 3 anemia (9%), and grade 3 fatigue (7%) [65] . Another study of BAY1238097 in eight patients with advanced solid tumors or NHL was halted given the development of DLTs such as grade 3 headache, grade 3 vomiting, and grade 3 low-back pain at subtherapeutic dose levels [66] . At the 2016 AACR Annual Meeting, a phase I study of GSK525762 in 70 patients with solid and hematologic malignancies, including 17 with NMC, was presented. Toxicities included thrombocytopenia (44%), nausea (40%), and vomiting; among 10 assessable patients with NMC, 2 PRs lasting 15 and 23 weeks and 4 patients with stable disease were observed [67] .
Additional studies of NMC patients have been small but revealing. An open label, dose escalation substudy of TEN-010 in patients with NMC, the prototypic yet rare carcinoma caused by a Brd4 fusion oncoprotein, identified two patients with responses after 2-3 weeks of treatment. This compound is particularly interesting because it is structurally related to JQ1 but has a longer half-life [68] . A case series of four patients with NMC treated with OTX015 on a compassionate need basis illustrates the potential benefits and pitfalls of single agent BET inhibition. Two of the four patients had rapid clinical responses in <2 weeks with symptomatic improvement. However, one experienced disease progression after 8 months of treatment and the other had progression at only 2 months. In the latter, repeat biopsy demonstrated intact Myc levels demonstrated by IHC staining suggesting that reversal of MYC suppression may have been one mechanism of acquired resistance to the drug. The major DLT observed was grade 3 and 4 thrombocytopenia that resolved when the drug was stopped [69] . Thus, preliminary results of BET inhibitors in NMC and hematologic malignancies have been modest, in that responses are few and short-lived. Furthermore, this limited data suggest that MYC dysregulation does not appear to predict response, nor do responders appear to be characterized by MYC downregulation.
The promise of combination therapy
Despite these mixed results, preclinical work suggests that BET inhibitors may have a promising future when utilized in combination with other agents. The effect of combining a BET inhibitor with a second agent, based on preclinical data, can be synergistic in multiple ways (Table 3) . In some cases, the combination induces a cytotoxic affect where merely a cytostatic effect or in vivo prevention of tumor progression had previously been seen. In others, the combination is able to overcome resistance to a single targeted agent. BET inhibitors have also been observed to have particular synergy with immune checkpoint inhibitors and with other epigenetic agents as well.
In many instances, BET inhibition may only cause a cytostatic effect in the preclinical setting. Yet when combined with a targeted agent, cytotoxicity results. For example, JQ1 causes cell cycle arrest but not apoptosis in osteosarcoma cell lines and xenografts with no effect on c-Myc expression. When rapamycin was added, growth inhibition and significant c-Myc downregulation resulted [70] . A similar synergy was observed with CPI203 and rapamycin in pancreatic neuroendocrine tumor cells [71] . In ovarian cancer cell lines, BET inhibition with JQ1 alone caused only cell cycle arrest. However, when trametanib was added in vivo, synergistic reduction in tumor volume and weight was observed [72] . Synergy appears to be critical to achieving cytotoxicity in lymphoma. In multiple DLBCL cell lines, the BET inhibitor OTX015 exerts a mostly cytostatic effect. However, OTX015 demonstrated significant synergy in vitro with a number of standard anti-lymphoma agents, including everolimus, ibrutinib, idelalisib, vorinostat, rituximab, decitabine, and lenalidomide [73] .
Combinations of BET inhibitors and targeted therapies appear to have specific promise in the setting of acquired resistance to targeted therapy, a pervasive challenge in the era of precision medicine [74, 75] . For example, resistance commonly develops to targeted inhibitors in BRAFmt melanomas. However, JQ1 and vemurafenib have synergistic effects in BRAFmt xenograft models, with greater restriction of tumor growth and increased survival. Moreover, a set of genes necessary for cell cycle regulation, DNA repair, DNA replication, and anti-apoptotic regulation were downregulated with this combination but were not affected by either agent independently [76] .
BET inhibition also appears to overcome resistance to hormone blockade. In tamoxifen-resistant MCF7 breast cancer xenografts, JQ1 or fulvestrant alone resulted in moderate growth inhibition, with additional inhibition when the agents were combined [77] . Recent single agent work with BET inhibitors in CRPC suggests that BET inhibition may be able to overcome resistance to hormone blockade in this setting. A group of CRPC cell lines was found to be sensitive to JQ1, especially those with intact androgen receptor signaling. This appears to be because BRD4 associates directly with the androgen receptor; when JQ1 disrupts this interaction, the androgen receptor can no longer be recruited to target gene loci [78] . In two recent studies, JQ1 and ZEN-3694 both suppressed tumor growth in enzalutamide resistant CRPC xenografts [79, 80] . We eagerly await the findings of two ongoing studies that pair a BET inhibitor with enzalutamide in patients with metastatic CRPC (Table 1) which will help clarify if androgen and BET inhibition in combination will provide an additive effect or even induce cytotoxicity.
Early results suggest BET inhibitors may enhance the activity of cell cycle inhibitors, which mechanistically is a logical conclusion based on the normal involvement of BET proteins in cell cycle regulation. For example, the BET inhibitor BI894999 exhibited synergistic tumor growth inhibition and MYC repression when combined with the CDK9 inhibitors alvocidib and LDC000067 in AML xenografts [81] . Similar effects were seen with a combination of BET inhibitor and a CDK2 inhibitor [82] . Another early study suggests there may be a role for combinations of BET inhibitors and agents that disrupt DNA damage repair. In k 820 murine Mycinduced lymphoma xenografts, the combination of BET inhibitor RVX2135 and ataxia telangiectasia and Rad3-related protein (ATR) inhibitor AZ20 caused a synergistic delay in tumor onset. In k2749 murine Myc-induced lymphoma xenografts, the same combination caused a synergistic effect on WBC reduction and improved survival [83] . These combinations are an area of interest as BET inhibition is well known to halt the cell cycle, which could potentiate the effect of DNA damage repair inhibitors. Synergistic decrease in tumor size compared with either agent alone Gopalakrishnan et al. [97] JQ1 and lenalidomide NOD/SCID mice injected with BC-3 lymphoma cells
Synergistic reduction of weight (measure of ascites) and improved survival compared with either agent alone
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The role of immune checkpoint inhibition
Recent research suggests that BET proteins play a role in the regulation of the Programmed Death-1 (PD-1)/Programmed Death Ligand-1 (PD-L1) immune checkpoint axis, and that BET inhibitors may potentiate the anticancer effect of checkpoint inhibitors. BRD4 in particular regulates the expression of PD-L1 by localizing to the promoter of the CD274 gene and enabling its transcription. In an ID8-Defb29/Vegf-a syngeneic ovarian cancer xenograft, JQ1 suppressed tumor growth and expression of PD-L1 on immune and tumor cells and resulted in increased cytotoxic T cell activity [84] . When combined with an unidentified PD-1 inhibitor in a KRASmt NSCLC xenograft, JQ1 synergistically decreased tumor burden and improved xenograft survival [85] . In a study of INCB054329, a BET inhibitor being evaluated in clinical trials, combination with unidentified PD-1 and PD-L1 inhibitors resulted in synergistic suppression of tumor growth in multiple syngeneic murine tumor models. This effect was also seen when the BET inhibitor was combined with the indoleamine-2,3-dioxygenase 1 (IDO-1) inhibitor epacadostat suggesting that multiple immune checkpoints may interact with BET proteins [86] .
Epigenetic synergies
One of the most promising areas of synergy involves combining multiple epigenetic directed therapies. Preclinical data suggests such combinations may improve cytotoxicity while allowing each agent to be used at attenuated dosing, potentially avoiding the issue of overlapping toxicities. For example, the combination of BET inhibitor RVX2135 and HDAC inhibitors vorinostat or panobinostat in k820 murine Myc-driven lymphoma cells resulted in apoptosis at doses of each agent which only induced cell cycle arrest when used individually. In mice transplanted with 2749 lymphoma cells, the combination of RVX2135 and vorinostat induced a synergistic effect on progression free survival. Moreover, vorinostat was effective at a reduced dose, suggesting that toxicities resulting from combining agents might be decreased if individual agents can be given at an attenuated dose without affecting efficacy [87] . BET and HDAC co-inhibition also shows promise in high risk myeloid leukemia. In mice transplanted with OCI-AML3 (NPM1 mutated) and MOLM13 (FLT3-ITD mutated) leukemia cells, the combination of JQ1 and panobinostat synergistically increased survival and reduced expression of MYC, BCL2, and CDK6. The investigators theorized that synergy resulted from HDAC inhibitors inducing histone hyperacetylation leading to MYC and BCL2 downregulation, ultimately causing cells to become more dependent on BET-induced transcription of these genes. Thus, they argued, BET inhibition would eliminate the only source of Myc and Bcl-2, resulting in apoptosis [88] .
Synergy between BET and HDAC inhibitors has also been observed in solid tumor models. In ER þ and triple negative breast cancer cells, JQ1 and mocetinostat exhibited synergistic cytotoxicity. The combination also downregulated overlapping sets of genes involved in cell cycle regulation, including the Ras/MAPK pathway [89] . In melanoma, I-BET151 and the HDAC inhibitor LBH589 exhibited a synergistic effect on improved survival in vivo with sparing of normal melanocytes. The mechanism for this interaction appeared to be the upregulation of the BH3 proapoptotic protein BIM and downregulation of the anti-apoptotic proteins BCL2 and XIAP [90] . In MYC amplified neuroblastoma, a disease in which BET inhibitors have shown promise as single agents, synergistic apoptosis was observed with panobinostat and JQ1 in vitro while normal embryonic fibroblast cells were spared; the same effect was found in murine xenografts where decreased tumor growth was observed [91] . As in hematologic tumor models, combinations of BET inhibitors and HDAC inhibitors appear cytotoxic at reduced doses of individual agents [90, 92] . These findings are important for several reasons. It appears that significant synergy exists between BET inhibitors and HDAC inhibitors in multiple disease models. In many cases this effect can be achieved at doses which are not cytotoxic individually, suggesting that it may be possible to avoid excess toxicities in humans by using smaller doses than are used when these agents are administered individually. This is critical given the overlapping toxicities, particularly hematological ones, induced by these agents. However, not all HDAC inhibitors are created equal; in a panel of five DLBCL cell lines, synergy with the HDAC inhibitor romidepsin was significantly less than that with vorinostat, suggesting that different classes of HDAC inhibitors will have varying effects. The mechanisms for synergy are poorly understood and appear to diverge based on the disease model; a better understanding of why these combinations are effective preclinically will be critical to further preclinical and clinical investigation. Epigenetic synergies are not limited to combined BET and HDAC inhibition. Although less is known, preliminary data also suggest synergy when BET inhibitors are combined with demethylating agents or with novel epigenetic agents such as LSD1 inhibitors [59, 93, 94] . Finally, BET inhibition may be transformed by newer research with proteolysis targeting chimera (PROTAC) technology, which preliminarily appears more cytotoxic than pharmacologic BET inhibition in multiple tumor cell lines; perhaps this technology may enhance combination tolerance and synergy [95] .
Conclusion
Currently, clinicaltrials.gov lists 18 ongoing trials of BET inhibitors ( Table 1) . Two of these are phase I combination trials with exemestane or fulvestrant in ERþ breast cancer and with enzalutamide in prostate cancer. The other 16 are single agent phase I or phase I/II trials. As we have seen, preliminary evidence from the laboratory and the clinic has shown that BET inhibitors are unlikely to provide durable cytotoxic effects in human cancers when administered as single agents. However, the promise of combinations, with targeted small molecule inhibitors, immune checkpoint inhibitors, and other epigenetic therapies, is significant. While such combinations may be limited by the toxicity profile of BET inhibitors, studies with HDAC inhibitors suggest that combinations may be effective with reduced doses, potentially limiting toxicities. It is critical going forward that investigators consider new combinations while collecting pharmacodynamic data that can help interpret why certain combinations may or may not be effective. The combined toxicities of such combinations may be significant, and must remain a major focus of any combination research strategy [96] .
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